Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein
Authors:
- 11 March 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (5) , 813-824
Abstract
Invariant natural killer T (iNKT) cells comprise a unique lineage of CD1d-restricted lipid-reactive T lymphocytes that potently kill tumor cells and exhibit robust immunostimulatory functions. Optimal tumor-directed iNKT cell responses often require expression of the antigen-presenting molecule CD1d on tumors; however, many tumor cells downregulate CD1d and thus evade iNKT cell recognition. We generated a soluble bispecific fusion protein designed to direct iNKT cells to the site of B-cell cancers in a tumor antigen-specific but CD1d-independent manner. This fusion protein is composed of a human CD1d molecule joined to a single chain antibody FV fragment specific for CD19, an antigen widely expressed on B-cell cancers. The CD1d-CD19 fusion protein binds specifically to CD19-expressing, but not CD19-negative cells. Once loaded with the iNKT cell lipid agonist α-galactosyl ceramide (αGC), the CD1d-CD19 fusion induces robust in vitro activation of and cytokine production by human iNKT cells. iNKT cells stimulated by the αGC-loaded CD1d-CD19 fusion also strongly transactivate T-, B-, and NK-cell responses and promote dendritic cell maturation. Importantly, the αGC-loaded fusion induces robust lysis of CD19+CD1d− Epstein-Barr virus immortalized human B-lymphoblastoid cell lines that are otherwise resistant to iNKT cell killing. Consistent with these findings; administration of the αGC-loaded fusion protein controlled the growth of CD19+CD1d− tumors in vivo, suggesting that it can “link” iNKT cells and CD19+CD1d− targets in a therapeutically beneficial manner. Taken together, these preclinical studies demonstrate that this B cell–directed fusion protein can be used to effectively induce iNKT cell antitumor responses in vitro and in vivo. Key Points The CD1d-CD19 fusion binds to CD19+ targets and, once loaded with αGC, promotes iNKT cell activation. The αGC-loaded CD1d-CD19 fusion induces robust iNKT cell lysis of CD19+ tumor cells in vitro and controls their growth in vivo. Visual AbstractKeywords
This publication has 43 references indexed in Scilit:
- Invariant natural killer T cells: an innate activation scheme linked to diverse effector functionsNature Reviews Immunology, 2013
- Natural killer cell subsets and natural killer–like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic featuresHuman Pathology, 2011
- Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic PotencyThe Journal of Immunology, 2010
- Invariant natural killer T cells: bridging innate and adaptive immunityCell and tissue research, 2010
- Regulation of multiple myeloma survival and progression by CD1dBlood, 2009
- A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung CancerThe Journal of Immunology, 2009
- Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphomaBlood, 2008
- Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in miceJournal of Clinical Investigation, 2008
- CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cellsLeukemia & Lymphoma, 2006
- Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsJournal of Experimental Medicine, 2005